Latest news with #EAP
Cision Canada
3 days ago
- Business
- Cision Canada
CPP Investments to Sell Stake in Encino Acquisition Partners
TORONTO, May 30, 2025 /CNW/ - Canada Pension Plan Investment Board (CPP Investments) today announced the sale of its entire stake in Encino Acquisition Partners (EAP), a leading oil and gas producer in Ohio, to EOG Resources. EOG Resources will acquire EAP for US$5.6 billion, inclusive of EAP's net debt. EAP was established by CPP Investments and Encino Energy in 2017 to acquire high-quality oil and gas assets with an established base of production in mature basins across the lower 48 states in the United States. Since 2017 CPP Investments has held a 98% ownership position in EAP alongside Encino Energy. Encino Energy will also be exiting from EAP, representing a full sale to EOG Resources. "When we established Encino Acquisition Partners with Encino Energy in 2017 we envisioned creating a company that would be a leader in acquiring U.S. oil and gas assets. Since then, it has done just that, and we are pleased with EAP's success and the strong returns this investment has delivered," said Bill Rogers, Head of Sustainable Energies at CPP Investments. The transaction is expected to close in the second half of 2025, subject to the satisfaction of customary closing conditions and regulatory approvals. CPP Investments' Sustainable Energies group is active across the global energy system, with net assets totaling approximately C$36.3 billion as at March 31, 2025, including investments in renewables, conventional energy, carbon capture and storage, distributed and energy services, and emerging and disruptive technologies. About CPP Investments Canada Pension Plan Investment Board (CPP Investments™) is a professional investment management organization that manages the Canada Pension Plan Fund in the best interests of the more than 22 million contributors and beneficiaries. In order to build diversified portfolios of assets, we make investments around the world in public equities, private equities, real estate, infrastructure and fixed income. Headquartered in Toronto, with offices in Hong Kong, London, Mumbai, New York City, San Francisco, São Paulo and Sydney, CPP Investments is governed and managed independently of the Canada Pension Plan and at arm's length from governments. At March 31, 2025, the Fund totalled $714.4 billion. For more information, please visit or follow us on LinkedIn, Instagram or on X @CPPInvestments.
Yahoo
3 days ago
- Business
- Yahoo
CPP Investments to Sell Stake in Encino Acquisition Partners
TORONTO, May 30, 2025 /CNW/ - Canada Pension Plan Investment Board (CPP Investments) today announced the sale of its entire stake in Encino Acquisition Partners (EAP), a leading oil and gas producer in Ohio, to EOG Resources. EOG Resources will acquire EAP for US$5.6 billion, inclusive of EAP's net debt. EAP was established by CPP Investments and Encino Energy in 2017 to acquire high-quality oil and gas assets with an established base of production in mature basins across the lower 48 states in the United States. Since 2017 CPP Investments has held a 98% ownership position in EAP alongside Encino Energy. Encino Energy will also be exiting from EAP, representing a full sale to EOG Resources. "When we established Encino Acquisition Partners with Encino Energy in 2017 we envisioned creating a company that would be a leader in acquiring U.S. oil and gas assets. Since then, it has done just that, and we are pleased with EAP's success and the strong returns this investment has delivered," said Bill Rogers, Head of Sustainable Energies at CPP Investments. The transaction is expected to close in the second half of 2025, subject to the satisfaction of customary closing conditions and regulatory approvals. CPP Investments' Sustainable Energies group is active across the global energy system, with net assets totaling approximately C$36.3 billion as at March 31, 2025, including investments in renewables, conventional energy, carbon capture and storage, distributed and energy services, and emerging and disruptive technologies. About CPP InvestmentsCanada Pension Plan Investment Board (CPP Investments™) is a professional investment management organization that manages the Canada Pension Plan Fund in the best interests of the more than 22 million contributors and beneficiaries. In order to build diversified portfolios of assets, we make investments around the world in public equities, private equities, real estate, infrastructure and fixed income. Headquartered in Toronto, with offices in Hong Kong, London, Mumbai, New York City, San Francisco, São Paulo and Sydney, CPP Investments is governed and managed independently of the Canada Pension Plan and at arm's length from governments. At March 31, 2025, the Fund totalled $714.4 billion. For more information, please visit or follow us on LinkedIn, Instagram or on X @CPPInvestments. SOURCE Canada Pension Plan Investment Board View original content to download multimedia:
STV News
4 days ago
- Health
- STV News
Hope for families as new medication rolled out to first Scottish children
Families of children living with a progressive muscle-wasting condition have welcomed the roll-out of a new drug that could slow the impact of the disease. They have been fighting for months to gain access to medication for Duchenne muscular dystrophy (DMD), which is found almost exclusively in boys. The condition has a massive impact on mobility and eventually begins to affect a patient's organs. The average life expectancy for someone with Duchenne is roughly 29 years. Givinostat, which can slow progression by months or even years, is currently awaiting approval for NHS use, but an early access programme (EAP) is available for those who qualify. Families had previously been told that limited resources would delay their children from receiving the treatment.A campaign put pressure on health boards and health secretary Neil Gray to find a way to speed up the was backed by high-profile Glasgow lawyer Aamer Anwar, who was prepared to support the families with legal the first of what's thought to be 30 eligible boys have begun to receive their first doses of givinostat. One of those is ten-year-old Riley Wilson from Angus. His 'Nana' Janice hopes the medication will make a big difference. She told STV News: 'I would have imagined he would have been in a wheelchair within a couple of years, but with this drug, hopefully that might be extended until he's into his mid-teens.'It's not a cure, we all know it's not a cure. But hopefully it will slow down the process of the disease and give them a lot longer on their feet.'Riley is feeling the impact of Duchenne – his aunt Joanne says stairs are 'a real struggle' for him.'He struggles to hold on, and if he's taking his (Nintendo) Switch or that upstairs, he needs a hand,' she the youngster is still able to do most of what he enjoys, like going to the park and playing football with his friends – something it's hoped givinostat will allow him to enjoy for for prescribing givinostat vary between health boards, but more are expecting to begin handing out the drug in the coming weeks. Eight-year-old Sam Millar and his parents, Stephen and Karla, have been at the forefront of the campaign. STV News Dad Stephen told STV News: 'We got a telephone call from Sam's consultant at the Sick Children's Hospital in Edinburgh to let us know that Sam will be getting the givinostat medication from the end of July, early August.'It's been very emotional. Immediately after the call, Karla just burst into tears, and I think that sums up what this means to us as a family.'Karla added: 'It's a bit like a weight has slightly lifted off your shoulders.'Obviously, the fight is not over until we have the medication in our hands and we start giving it to Sam.'While DMD is a rare condition, around 2,500 people in total around the UK are living with the disease. Campaigners hope givinostat can be given to more than the roughly 30 children currently set to receive the drug in said: 'It will take a wee while for all the boys to get this.'But the boys who are non-ambulant (unable to walk independently), they are now the ones who we need to fight for.'Emily Reuben, the chief executive of Duchenne UK, and Alex Johnson, the chief executive of Joining Jack, both have a son with said: 'There's something worse than having no treatment – and that's having a treatment, available to the NHS for free, but no one can work out how to administer it.'I'm delighted that clinics in Scotland have solved this problem and are committed to rolling out access to the EAP for their patients. 'Now is the time for the rest of the UK to follow Scotland's example and provide a plan and timescale to roll this out for everyone who is eligible.' Health secretary Neil Gray said: 'I understand this is an anxious time for the young people and their families and recognise how much it affects their lives. 'I welcome the roll-out of the early access programme for givinostat for eligible children who have been diagnosed with Duchenne Muscular Dystrophy and who are still walking. 'The Scottish Government wants all children and young people living with DMD to benefit from new medicines, such as givinostat, and live longer, fuller lives. Health Boards have now started to contact all families with children eligible under the current national early access programme, to set out the timelines involved. 'We continue to work with the four Health Boards providing regional services to those with DMD in order to support access to givinostat as soon as possible for all children who have been diagnosed with DMD, including those who are not able to walk.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Time Business News
6 days ago
- Health
- Time Business News
Best Insurance Plans for Mental Health Coverage 2025
In 2025, prioritizing mental health is more important than ever. As awareness grows and stigma decreases, access to reliable insurance plans that include robust mental health coverage has become a vital part of comprehensive healthcare. Whether you're looking for therapy, medication, or inpatient treatment, the right insurance can make these services more affordable and accessible. This guide outlines some of the best options available in 2025. Insurance Plans for Mental Health Coverage UnitedHealthcare (UHC) stands out for its wide provider network and commitment to behavioral health. UHC offers various programs like 24/7 virtual mental health visits, an extensive network of in-person therapists, and an Employee Assistance Program (EAP). Their coverage includes therapy, substance use treatment, and crisis care, making it one of the most well-rounded choices available today. Learn more about UHC mental health benefits and how they can support your well-being throughout the year. Cigna Healthcare is another strong contender, offering a seamless digital experience and access to both traditional and alternative mental health therapies. With options like personalized coaching and virtual sessions, Cigna appeals especially to younger populations who value convenience and digital-first experiences. Anthem Blue Cross Blue Shield includes behavioral health as part of their essential benefits under ACA-compliant plans. Their telehealth expansion in 2025 further supports remote therapy and mental health consultation, making care more reachable than ever. Other notable mentions include Oscar Health and Kaiser Permanente, both of which continue to grow their mental health support services, with Kaiser focusing on integrated care and Oscar leveraging tech-driven member engagement. To address growing demand, many plans now offer more flexible policies, with expanded coverage for preventive therapy sessions, youth mental health programs, and even stress-management tools. Mental health parity laws have also strengthened, requiring insurers to treat mental health on par with physical health, which has pushed more providers to refine their offerings. Many employers are now offering expanded mental wellness benefits as part of group plans to improve productivity and satisfaction across their workforce. This shift toward proactive care means that therapy is now seen as a vital wellness tool, not just a crisis response. Conclusion Choosing the best mental health insurance plan in 2025 involves more than comparing premiums—it's about understanding the level of support, network accessibility, and how well a plan fits your unique needs. Providers like UnitedHealthcare, Cigna, and Anthem are leading the charge in offering flexible, comprehensive coverage that prioritizes your mental well-being. With more tools, more providers, and better access than ever before, now is the time to invest in your mental health through the right insurance partner. TIME BUSINESS NEWS
Business Wire
14-05-2025
- Business
- Business Wire
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress
LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that updated data from its Early Access Program for 173 patients with aGvHD treated with MaaT013 have been selected for oral presentation at the European Hematology Association (EHA) Annual congress, taking place in Milan from June 12–15, 2025. The oral presentation of MaaT013 data at EHA—Europe's leading hematology conference—underlines the growing recognition of the drug's clinical potential and the Company's leadership in hemato-oncology using microbiome-based approach. These updated EAP results for 173 patients, to be presented at EHA Congress, are consistent with the positive topline results of the Phase 3 trial announced in January 2025 and further confirm MaaT013's high efficacy and favorable safety profile in treating patients with gastrointestinal aGvHD. There are currently no approved options for patients with GI-aGvHD who are refractory to steroids and either refractory or intolerant to ruxolitinib, despite the poor prognosis with one-year survival rates of 15% (Abedin et al., 2021). MaaT Pharma has observed a 75% increase in physician demand with MaaT013 under the ongoing EAP in 2024 compared to 2023, across Europe and, more recently, in the United States. This steady demand for access to MaaT013 reflects its growing adoption by the medical community as a treatment option for patients with GI-aGvHD. To date, the Company has safely treated more than 300 patients with aGvHD across clinical trials and the Company's EAP ongoing in both Europe and the U.S. With upcoming regulatory milestones in Europe including a Marketing Authorization submission expected in June 2025, growing global physician interest, and continued clinical validation, MaaT013 has the potential to become the first approved third-line treatment for GI-aGvHD, significantly improving survival outcomes for approximately 3,000 third-line patients annually across the U.S., Canada, and Europe. Details of the Oral Presentation: Title: Pooled Fecal Allogeneic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in Europe Abstract number: S260 Presenting Author: Mohamad Mohty, Professor of Hematology and Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University Session title: s424 Stem cell transplantation - Session 2 Date & Time: 13/06/2025 (17:00 - 18:15 CEST) - Brown Hall 3 MaaT Pharma will also present its ongoing Phase 2b trial (PHOEBUS) design for MaaT033 developed as an adjunctive therapy to enhance overall survival in allo-HSCT. This international, multi-center trial (NCT05762211) is the largest randomized controlled study to date of a microbiome-based therapy in oncology, enrolling up to 387 patients across 60 sites. To date, the independent Data Safety Monitoring Board (DSMB) has conducted two safety reviews and one unblinded interim analysis, all of which concluded positively with the recommendation that the PHOEBUS trial proceed as planned. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
